interesting. I think the gist of the CRC risk had been mentioned here a lot. It is nice to see it quantified as about
2-fold increase. But the finding of no increased risk for non-Remicade (presumably non-biologic) folks is new.
I think the general wisdom I read on this forum has been the risk of not Remicade for CRC is likely greater than the risk of lymphoma from Remicade. (or at least no higher than 6mp/thiopurines)
Given that the phase-I and phase-III trials for Remicade had found some increased risk for lymphoma, it is interesting that this was not found in this study using a larger population sample.
It is not clear (from the abstract) if the non-Remicade group was untreated or well-managed with other meds. Some like 6mp carry their own risk of lymphoma. The exact composition of the groups being compared is always very important in approaching these kinds of results.
11/08: ischemic colitis and scope perf colon. 12cm colon/ileocecal resected. IV antib:sepsis.
01/10: Dx: Mod. UC pancolitis
. Rx: Lialda 3x.
02/11: Major flare w/antib:sinus. Rx: 40mg Pred taper.
07/11: Histol remiss rt/trans; worse sigmoid. Rx: Rowasa & hydrocort
Curr: 1-2 soft-formed stool, no urgency: Lialda 2x, NO PRED, probiotics, Vit-D/C